Chapter title |
A Compelling Case for the Use of Perioperative Zymogen Protein C for Increased Patient Safety.
|
---|---|
Chapter number | 2 |
Book title |
Oxygen Transport to Tissue XXXVIII
|
Published in |
Advances in experimental medicine and biology, January 2016
|
DOI | 10.1007/978-3-319-38810-6_2 |
Pubmed ID | |
Book ISBNs |
978-3-31-938808-3, 978-3-31-938810-6
|
Authors |
Duane. F. Bruley, J. M. Abdallah, M. B. Streiff, T. W. McGuire, K. C. Bruley, M. Duncan, R. Duncan, E. E. Thiessen, M. White, K. C. Bruley Jr., S. B. Bruley, K. C. BruleyJr. |
Editors |
Qingming Luo, Lin Z. Li, David K. Harrison, Hua Shi, Duane F. Bruley |
Abstract |
It is imperative to maintain normal blood flow to provide adequate oxygen supply to specific organs and cells, as well as for the removal of metabolic byproducts. Therefore, any situation that results in blood clotting can injure or kill living tissues. In this paper, we describe a case where a protein C deficient subject who would, by all medical indicators, be at 100 % risk of experiencing thrombophlebitis, deep vein thrombosis, and or lung emboli, is able to escape all pathologies by using perioperative zymogen protein C (ZPC). This protein C deficient patient has a long history of blood clotting, particularly from surgical procedures. The patient is 81 years old and first experienced clotting due to hernia surgery in 1964, when he was hospitalized for 16 days post-surgery with life threatening complications. It was later determined in 1980, after many episodes, that the patient had hereditary protein C deficiency at the 38 % level. In his hernia surgery, perioperative ZPC was used along with accepted anticoagulation procedures with no blood clots or other related side effects occurring. This procedure can greatly benefit protein C deficient patients, and could potentially find use for non-PC deficient patients in surgeries and a variety of other medical treatments. This particular case helps to validate the importance of ZPC in effecting safer surgery in high-risk patients. It also supports the mechanism of ZPC acting as an anticoagulant without causing bleeding. Most importantly, each clinical case study represents a unique combination of surgeon, hematologist, medical staff, and patient functioning as a coordinated team. In this case, smaller amounts of very expensive ZPC achieved safe and efficacious results, which is hugely important for future clinical applications when considering the production cost of ZPC. More studies must be done to establish minimum dosing while achieving safe and efficacious outcomes. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 22 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 3 | 14% |
Student > Postgraduate | 3 | 14% |
Student > Master | 3 | 14% |
Researcher | 2 | 9% |
Student > Bachelor | 2 | 9% |
Other | 3 | 14% |
Unknown | 6 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 5 | 23% |
Social Sciences | 3 | 14% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 9% |
Engineering | 2 | 9% |
Biochemistry, Genetics and Molecular Biology | 1 | 5% |
Other | 1 | 5% |
Unknown | 8 | 36% |